CY1119702T1 - Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης - Google Patents

Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης

Info

Publication number
CY1119702T1
CY1119702T1 CY20171101078T CY171101078T CY1119702T1 CY 1119702 T1 CY1119702 T1 CY 1119702T1 CY 20171101078 T CY20171101078 T CY 20171101078T CY 171101078 T CY171101078 T CY 171101078T CY 1119702 T1 CY1119702 T1 CY 1119702T1
Authority
CY
Cyprus
Prior art keywords
pyrido
dyydro
oxazine
producer
solid form
Prior art date
Application number
CY20171101078T
Other languages
English (en)
Inventor
Konstanze Hurth
Christoph KALIS
Karen KAMMERTOENS
Nicolas Soldermann
Frédéric ZECRI
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51019963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119702(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119702T1 publication Critical patent/CY1119702T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η ευρεσιτεχνία αναφέρεται σε μια άνυδρη κρυσταλλική μορφή της (1,1-διοξο-εξαϋδρο-1λάμδα*6*-θειοπυραν-4-υλ) - {(S)-3-[1-(6-μεθοξυ-5-μεθυλο-πυριδινο-3-υλ) -2,3-διυδρο-1Η-πυριδο[3,4-b] [1,4]οξαζιν-7-υλοξυ]-πυρρολιδιν-1-υλ}-μεθανόνης• φαρμακευτικές συνθέσεις και συνδυασμούς που περιλαμβάνουν αυτές τις μορφές όπως επίσης και σε μεθόδους χρήσης αυτών των μορφών, συμπεριλαμβανομένων των φαρμακευτικών τους συνθέσεων και συνδυασμών για τη θεραπεία νόσων.
CY20171101078T 2012-11-26 2017-10-13 Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης CY1119702T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
IR1391307213 2012-12-04
PCT/IB2013/060412 WO2014102630A1 (en) 2012-11-26 2013-11-26 Solid form of dihydro-pyrido-oxazine derivative

Publications (1)

Publication Number Publication Date
CY1119702T1 true CY1119702T1 (el) 2018-06-27

Family

ID=51019963

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101078T CY1119702T1 (el) 2012-11-26 2017-10-13 Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης

Country Status (23)

Country Link
EP (1) EP2928896B1 (el)
KR (1) KR102184069B1 (el)
CN (1) CN104870451B (el)
AU (1) AU2013368997B8 (el)
BR (1) BR112015009870A2 (el)
CA (1) CA2891521A1 (el)
CL (1) CL2015001409A1 (el)
CY (1) CY1119702T1 (el)
DK (1) DK2928896T3 (el)
GT (1) GT201500124A (el)
HK (1) HK1209419A1 (el)
IL (1) IL238889B (el)
MX (1) MX366342B (el)
NZ (1) NZ706865A (el)
PE (1) PE20150946A1 (el)
PH (1) PH12015501052A1 (el)
PL (1) PL2928896T3 (el)
PT (1) PT2928896T (el)
SG (1) SG11201503410VA (el)
TN (1) TN2015000128A1 (el)
TW (1) TW201422625A (el)
WO (1) WO2014102630A1 (el)
ZA (1) ZA201502350B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2794600T (pt) 2011-12-22 2018-03-13 Novartis Ag Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
RU2769507C1 (ru) 2018-08-13 2022-04-01 Ф. Хоффманн-Ля Рош Аг Новые гетероциклические соединения как ингибиторы моноацилглицеринлипазы
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (el) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE122005000053I2 (de) 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
PT836605E (pt) 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
ES2249800T3 (es) 1996-06-24 2006-04-01 Pfizer Inc. Derivados triciclicos sustituidos con fenilamino para el tratamento de enfermedades hiperproliferativas.
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
EP0938597B1 (en) 1996-09-06 2003-08-20 Obducat Aktiebolag Method for anisotropic etching of structures in conducting materials
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CA2269118C (en) 1996-11-18 2012-05-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
KR20070087132A (ko) 1998-11-20 2007-08-27 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법및 물질
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
IL155618A0 (en) 2000-11-07 2003-11-23 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
EP1578411A4 (en) 2002-12-09 2007-05-02 Univ Texas PROCESS FOR SELECTIVE INHIBITION OF JANUS TYROSINE KINASE 3 (JAK3)
PT1704145E (pt) 2004-01-12 2012-09-04 Ym Biosciences Australia Pty Inibidores de quinase seletivos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ZA200802080B (en) * 2005-09-07 2009-09-30 Serono Lab P13K inhibitors for the treatment of endometriosis
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
PT2794600T (pt) * 2011-12-22 2018-03-13 Novartis Ag Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide

Also Published As

Publication number Publication date
WO2014102630A1 (en) 2014-07-03
SG11201503410VA (en) 2015-05-28
CL2015001409A1 (es) 2015-07-24
AU2013368997A8 (en) 2015-10-08
KR20150091047A (ko) 2015-08-07
DK2928896T3 (da) 2017-11-06
PL2928896T3 (pl) 2018-01-31
AU2013368997B8 (en) 2015-10-08
ZA201502350B (en) 2017-08-30
PT2928896T (pt) 2017-10-25
CN104870451B (zh) 2017-07-07
CN104870451A (zh) 2015-08-26
KR102184069B1 (ko) 2020-11-30
GT201500124A (es) 2016-03-01
EP2928896A1 (en) 2015-10-14
PE20150946A1 (es) 2015-06-28
MX366342B (es) 2019-07-05
PH12015501052A1 (en) 2015-07-27
BR112015009870A2 (pt) 2017-12-05
MX2015006650A (es) 2015-08-10
AU2013368997B2 (en) 2015-09-24
HK1209419A1 (en) 2016-04-01
TN2015000128A1 (en) 2016-10-03
EP2928896B1 (en) 2017-07-19
IL238889A0 (en) 2015-07-30
IL238889B (en) 2021-03-25
NZ706865A (en) 2016-04-29
CA2891521A1 (en) 2014-07-03
AU2013368997A1 (en) 2015-04-30
TW201422625A (zh) 2014-06-16

Similar Documents

Publication Publication Date Title
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA201100299A1 (ru) Органические соединения
EA201170772A1 (ru) Органические соединения
EA201390381A1 (ru) Триазиноксадиазолы
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201071320A1 (ru) Активаторы глюкокиназы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
IN2014CN03597A (el)
CU24398B1 (es) 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
CY1119702T1 (el) Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης
CY1117723T1 (el) Παραγωγα στερολης, μεθοδος για την παρασκευη των ιδιων, φαρμακευτικες συνθεσεις οι οποιες περιεχουν τα ιδια και χρηση αυτων για την αγωγη πολλαπλων γλοιοβλαστωματων